UroToday3d
Prospective Comparison of 68Ga-NeoB and 68Ga-PSMA-R2 PET/MRI in Patients with Biochemically Recurrent Prostate Cancer - Beyond the Abstract
Managing biochemically recurrent prostate cancer is challenging when conventional imaging like CT and MRI fails to identify recurrent disease, particularly at low PSA levels. Treatment can be given ...
UroToday3d
A Case of Rapidly Progressive De Novo Metastatic Small-Cell Neuroendocrine Prostate Cancer.
Introduction: Neuroendocrine/small-cell prostate cancer (NEPC) is a rare and aggressive subtype of prostate cancer, which typically develops after prolonged treatment ...
UroToday3d
Evaluating the Impact of a Shared Decision-making Intervention for Patients with Renal Cell Carcinoma: The SDM-RCC Study Protocol.
The aim of the SDM-RCC study is to evaluate the impact of a comprehensive shared decision-making (SDM) intervention for patients with renal cell carcinoma (RCC) on the decision-making process and ...
UroToday3d
Perioperative and Extended Outcomes of Patients Undergoing Parastomal Hernia Repair Following Cystectomy and Ileal Conduit - Beyond the Abstract
Radical cystectomy (RC) with urinary diversion remains the gold standard for muscle-invasive bladder cancer as well as high-risk non-invasive variants, with a higher proportion of patients receiving ...
UroToday3d
Adult Prostate Sarcoma: Demographics, Treatment Patterns, and Survival.
This study aimed to examine clinicopathologic characteristics, treatment patterns, and survival rates in a contemporary population-based cohort of adult prostate sarcoma patients. In the Surveillance, ...
UroToday3d
Prognostic significance of the PI-RADS score in men with prostate cancer undergoing radical prostatectomy.
MRI-targeted biopsy (T-Bx) for which Prostate Imaging Reporting and Data System (PI-RADS) assessment categories are useful has been shown to more accurately detect clinically significant prostate ...
UroToday4d
Identifying Barriers to Timely Follow-up After Elevated PSA Screening: A Retrospective Analysis of a Large Healthcare System - Beyond the Abstract
Our research, titled "Identifying Barriers to Timely Follow-up After Elevated PSA Screening: A Retrospective Analysis of a Large Healthcare System," analyzed follow-up patterns for over 28,000 ...
UroToday4d
Advances in prostate cancer treatment: Radionuclide therapy for prostate cancer.
The optimal treatment of metastatic castration-resistant prostate cancer (mCRPC) continues to be challenging, given the multitude of life prolonging treatment options. Radionuclide therapy delivers ...
UroToday4d
Long-term Clinical Outcomes of Patients With Negative Pathology (pN0) at Primary Retroperitoneal Lymph Node Dissection.
Patients who undergo primary retroperitoneal lymph node dissection (pRPLND) for early-stage testicular cancer and have no cancer (pN0) found in the retroperitoneum are believed to have an excellent ...
UroToday4d
Cost-effectiveness of first-line enfortumab vedotin in addition to pembrolizumab for metastatic urothelial carcinoma in the United States.
The EV-302 trial found that the combination of enfortumab vedotin (EV) with pembrolizumab significantly improved survival for patients with metastatic urothelial carcinoma (mUC). However, given the ...
UroToday4d
Biology-guided radiotherapy in metastatic prostate cancer: time to push the envelope?
The therapeutic landscape of metastatic prostate cancer has undergone a profound revolution in recent years. In addition to the introduction of novel molecules in the clinics, the field has witnessed ...
UroToday4d
Neurologic Symptoms after 177Lu-Prostate-Specific-Membrane Antigen-617 Therapy: A Single-Center Experience - Beyond the Abstract
In our recent publication in the Journal of Nuclear Medicine, we examined the potential neurologic symptoms following 177Lu-PSMA-617 therapy in patients with metastatic castration-resistant prostate ...